Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Barriers to PrEP use and adherence among adolescent girls and young women in Eastern, Southern, and Western Africa: a scoping review.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101088690 Publication Model: Electronic Cited Medium: Internet ISSN: 1472-6874 (Electronic) Linking ISSN: 14726874 NLM ISO Abbreviation: BMC Womens Health Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: [London] : BioMed Central, 2001-
    • الموضوع:
    • نبذة مختصرة :
      Competing Interests: Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
      Background: Adolescent girls and young women (AGYW) are disproportionately affected by HIV. Globally, in 2022, an estimated 4000 AGYW 15-24 were newly infected with HIV weekly, and nearly 78% of these infections occurred in sub-Saharan Africa. Oral Pre-Exposure Prophylaxis (PrEP) is a key HIV prevention option within an overall HIV combination prevention approach with an efficacy of over 90% when taken correctly. However, uptake of and adherence to PrEP remains low, particularly among AGYW. This scoping review aims to map available evidence on factors that limit PrEP use among AGYW in Eastern, Southern, and Western African countries to inform research, policy, and practice on delivery of PrEP. Our review identified factors that affect PrEP journey among AGYW along the HIV prevention cascade.
      Methods: Guided by Arksey and O'Malley framework and using the PRISMA extension for scoping reviews, we searched the Web of Science, Global Health, and PubMed databases. Our review focused on oral PrEP, specifically papers reporting on barriers to PrEP experienced by AGYW, and peer-reviewed English-language articles published between 2012 and 2023.
      Results: Of 1063 papers screened, 25 were included. Over half (60%) of the studies were qualitative; 72% were conducted in Kenya and South Africa. The barriers affecting motivation were, fear of side effects and pill burden, percieved low HIV risk, perceived stigma, PrEP use disapproval from parents and partners. PrEP access was limited by healthcare providers' stigma, isolated clinic setup, and lack of resources. Effective PrEP use was limited by a lack of parental or partner support, stigma, and lifestyle changes.
      Conclusions: Adolescent girls and young women face multiple and often intersecting barriers to effective PrEP use with stigma being a factor cross-cutting all steps of the prevention cascade. Similarly, lack of social support, reflected through disapproval and judgmental attitudes and low HIV risk perception, also affected two steps of the prevention cascade. Our review identified gaps in available evidence, with most studies conducted in only two countries and few quantitative studies available. Improving PrEP uptake and adherence requires interventions that address barriers across the cascade, with a particular focus on stigma and social support.
      (© 2024. The Author(s).)
    • References:
      AIDS Behav. 2021 Jul;25(7):2046-2053. (PMID: 33389323)
      JAMA. 2019 Jun 11;321(22):2214-2230. (PMID: 31184746)
      J Int AIDS Soc. 2024 Feb;27(2):e26213. (PMID: 38379129)
      AIDS Behav. 2018 Nov;22(11):3468-3479. (PMID: 29404757)
      PLoS Med. 2022 Sep 12;19(9):e1004097. (PMID: 36095005)
      PLoS One. 2021 Mar 5;16(3):e0248307. (PMID: 33667264)
      AIDS Behav. 2021 Jul;25(7):2054-2070. (PMID: 33389319)
      Lancet HIV. 2019 Jan 1;6(1):e60-e66. (PMID: 32066995)
      J Int AIDS Soc. 2022 May;25(5):e25909. (PMID: 35543110)
      AIDS Behav. 2022 Jul;26(7):2376-2386. (PMID: 35061115)
      JAMA. 2024 Mar 19;331(11):930-937. (PMID: 38427359)
      BMC Health Serv Res. 2021 Oct 18;21(1):1112. (PMID: 34663320)
      Front Reprod Health. 2023 Jan 09;4:1086558. (PMID: 36699145)
      N Engl J Med. 2010 Dec 30;363(27):2587-99. (PMID: 21091279)
      AIDS Res Ther. 2020 Sep 7;17(1):55. (PMID: 32894138)
      Womens Health (Lond). 2022 Jan-Dec;18:17455057221087117. (PMID: 35306944)
      J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958219831011. (PMID: 30776954)
      BMC Public Health. 2022 Oct 14;22(1):1916. (PMID: 36242000)
      Lancet. 2008 Aug 30;372(9640):764-75. (PMID: 18687460)
      AIDS Patient Care STDS. 2020 Aug;34(8):336-343. (PMID: 32757980)
      PLoS One. 2018 May 31;13(5):e0197479. (PMID: 29851988)
      J Assoc Nurses AIDS Care. 2020 Nov-Dec;31(6):669-677. (PMID: 32675642)
      AIDS. 2022 Jul 1;36(8):1151-1159. (PMID: 35579012)
      AIDS Behav. 2022 Dec;26(12):3950-3962. (PMID: 35776254)
      Curr Opin HIV AIDS. 2016 Jan;11(1):10-7. (PMID: 26633638)
      Curr HIV/AIDS Rep. 2021 Dec;18(6):490-499. (PMID: 34719745)
      PLoS One. 2021 Feb 17;16(2):e0246717. (PMID: 33596216)
      BMC Public Health. 2021 Jul 1;21(1):1284. (PMID: 34210288)
      J Int AIDS Soc. 2016 Jul 27;19(1):20749. (PMID: 27469061)
      Lancet. 2012 Jul 28;380(9839):325. (PMID: 22852138)
      J Int AIDS Soc. 2015 Jul 20;18(4 Suppl 3):20227. (PMID: 26198350)
      J Int AIDS Soc. 2021 Jun;24 Suppl 2:e25731. (PMID: 34164929)
      Arch Sex Behav. 2021 May;50(4):1729-1742. (PMID: 33954824)
      BMC Womens Health. 2022 Aug 16;22(1):344. (PMID: 35974360)
      AIDS Behav. 2023 Jan;27(1):134-149. (PMID: 35793053)
      BMC Public Health. 2020 Jul 16;20(1):1120. (PMID: 32677930)
      J Int AIDS Soc. 2023 Sep;26(9):e26175. (PMID: 37758649)
      Lancet. 2016 Jan 2;387(10013):53-60. (PMID: 26364263)
      BMC Public Health. 2021 Apr 14;21(1):727. (PMID: 33853575)
      JAMA. 2019 Jun 11;321(22):2203-2213. (PMID: 31184747)
      J Virus Erad. 2016 Jul 01;2(3):149-55. (PMID: 27482454)
      BMC Infect Dis. 2022 May 16;22(1):467. (PMID: 35578163)
      AIDS Behav. 2022 Sep;26(9):2881-2890. (PMID: 35218452)
      Child Abuse Negl. 2022 Dec;134:105927. (PMID: 36244210)
      Lancet. 2013 Jun 15;381(9883):2083-90. (PMID: 23769234)
      J Acquir Immune Defic Syndr. 2010 Jul;54 Suppl 1:S5-6. (PMID: 20571423)
      J Int AIDS Soc. 2014 Sep 08;17(3 Suppl 2):19157. (PMID: 25224616)
      J Int AIDS Soc. 2019 Jul;22 Suppl 4:e25309. (PMID: 31328375)
      Trials. 2021 Jul 26;22(1):489. (PMID: 34311754)
      AIDS Behav. 2022 Jan;26(1):147-159. (PMID: 34259963)
      Am J Nurs. 2014 Apr;114(4):53-6. (PMID: 24681476)
      MethodsX. 2021 May 07;8:101375. (PMID: 34430271)
      PLoS One. 2021 Oct 14;16(10):e0258542. (PMID: 34648589)
      AIDS Behav. 2021 Jul;25(7):2154-2165. (PMID: 33521908)
      BMC Infect Dis. 2022 Apr 23;22(1):399. (PMID: 35461220)
      PLoS Med. 2021 Nov 29;18(11):e1003866. (PMID: 34843468)
      J Acquir Immune Defic Syndr. 2017 May 1;75 Suppl 1:S17-S26. (PMID: 28398993)
      PLOS Glob Public Health. 2023 Jan 20;3(1):e0000636. (PMID: 36962727)
      J Acquir Immune Defic Syndr. 2022 Sep 1;91(1):17-25. (PMID: 35972852)
      J Int AIDS Soc. 2022 Jul;25(7):e25968. (PMID: 35872602)
      AIDS Behav. 2022 May;26(5):1618-1632. (PMID: 34716835)
      Pathogens. 2023 Jul 09;12(7):. (PMID: 37513771)
      AIDS Behav. 2023 Oct;27(10):3223-3238. (PMID: 37119401)
    • Contributed Indexing:
      Keywords: Adherence; Adolescent girls; HIV prevention; PrEP; Uptake; Young women
    • الرقم المعرف:
      0 (Anti-HIV Agents)
    • الموضوع:
      Date Created: 20241226 Date Completed: 20241226 Latest Revision: 20250130
    • الموضوع:
      20250130
    • الرقم المعرف:
      PMC11670510
    • الرقم المعرف:
      10.1186/s12905-024-03516-y
    • الرقم المعرف:
      39725977